Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
Conditions
Keywords
essential thrombocythemia, polycythemia vera, blastic phase chronic myelogenous leukemia, secondary myelodysplastic syndromes, previously treated myelodysplastic syndromes, adult acute myeloid leukemia in remission, childhood acute myeloid leukemia in remission, de novo myelodysplastic syndromes, secondary acute myeloid leukemia, accelerated phase chronic myelogenous leukemia, childhood chronic myelogenous leukemia, adult acute lymphoblastic leukemia in remission, childhood acute lymphoblastic leukemia in remission, recurrent adult acute myeloid leukemia, relapsing chronic myelogenous leukemia, recurrent childhood acute myeloid leukemia, chronic idiopathic myelofibrosis, atypical chronic myeloid leukemia, myelodysplastic/myeloproliferative disease, unclassifiable, adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with t(15;17)(q22;q12)
Brief summary
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well peripheral stem cell transplant works in treating patients with high-risk leukemia.
Detailed description
OBJECTIVES: * Determine the safety of a preparative regimen comprising total body irradiation, cyclophosphamide, thiotepa, and fludarabine, but without anti-thymocyte globulin, in patients with high-risk leukemia treated with peripheral blood stem cell transplantation from partially matched related donors. * Determine the incidence of graft failure, acute graft-versus-host disease (GVHD), and treatment-related mortality in patients treated with this regimen. * Determine rates of chronic GVHD and relapse in patients treated with this regimen. * Determine disease-free and overall survival in patients treated with this regimen. OUTLINE: This is a pilot study. Patients receive a preparative regimen comprising total lymphoid irradiation once daily on days -13 to -11; cyclophosphamide IV over 1 hour on days -8 and -7; thiotepa IV over 4 hours every 12 hours on day -6; fludarabine IV over 30 minutes on days -5 to -1; and total body irradiation once on day -1. Patients also receive cyclosporine IV over 12 hours on days -8 to -1 and methylprednisolone IV twice daily on days -3 and -2. Patients receive CD34-enriched T-cell-depleted allogeneic stem cell infusion on day 0. Patients with disease progression or uncontrolled infection but without grade II or greater graft-versus-host disease may receive up to 3 donor lymphocyte infusions at least 4 weeks apart until disease regression. Patients are followed at least weekly until day 100 and then at 6, 12, 18, 24, 36, and 48 months. PROJECTED ACCRUAL: A total of 20-51 patients will be accrued for this study.
Interventions
DRUGcyclophosphamide
DRUGcyclosporine
DRUGfludarabine phosphate
DRUGmethylprednisolone
DRUGtherapeutic allogeneic lymphocytes
DRUGthiotepa
PROCEDUREallogeneic bone marrow transplantation
PROCEDUREbiological therapy
PROCEDUREbone marrow ablation with stem cell support
PROCEDUREbone marrow transplantation
PROCEDUREchemotherapy
PROCEDUREleukocyte therapy
PROCEDUREperipheral blood lymphocyte therapy
PROCEDUREperipheral blood stem cell transplantation
PROCEDUREradiation therapy
Sponsors
National Heart, Lung, and Blood Institute (NHLBI)
Study design
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
10 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following: * High-risk myelodysplastic syndromes (MDS), meeting 1 of the following criteria: * Transformation to acute leukemia defined by at least 15% blasts * Secondary to prior treatment with chemotherapy and/or radiotherapy * Presence of complex cytogenetics (at least 3 karyotypic abnormalities) * Monosomy or deletion of chromosome 7 * Acute myeloid leukemia (AML), meeting 1 of the following criteria : * High-risk AML in first remission and meeting 1 of the following criteria: * At least 3 karyotypic abnormalities * Monosomy or deletion of chromosome 5 or 7 = 11q23 chromosomal abnormality * Prior diagnosis of MDS * Received prior radiotherapy or chemotherapy * In second or subsequent remission * Primary induction failure or partial remission * Untested or sensitive relapse * Chronic myelogenous leukemia, meeting 1 of the following criteria: * Blast crisis * Accelerated phase disease that has failed prior treatment with imatinib mesylate, defined as a failure to achieve hematologic response after 3 months of standard dose (600 mg/day) therapy or disease progression on therapy * Myeloproliferative disease * The following diagnoses are eligible: * Agnogenic myeloid metaplasia * Essential thrombocythemia * Polycythemia vera * Must have evidence of transformation to acute leukemia * Acute lymphocytic leukemia (ALL), meeting 1 of the following criteria: * High-risk ALL in first remission defined by 1 of the following: * t(9;22) or 11q23 chromosomal abnormality * Complete response at least 4 weeks after induction therapy OR requiring at least 2 induction regimens * Second or subsequent remission * No relapsed leukemia refractory to appropriate salvage therapy * Availability of an HLA-mismatched family donor * Donor age 75 or under * No better donor alternative (i.e., HLA-matched related or unrelated stem cell donor) is available PATIENT CHARACTERISTICS: Age * 10 to 50 Performance status * ECOG 0-1 Life expectancy * More than 3 months Hematopoietic * See Disease Characteristics Hepatic * Bilirubin no greater than 4 mg/dL * Transaminases no greater than 3 times upper limit of normal Renal * Creatinine no greater than 2.0 mg/dL OR * Creatinine clearance at least 60 mL/min Cardiovascular * LVEF at least 40% Pulmonary * DLCO at least 65% of predicted Other * Not pregnant * Negative pregnancy test * HIV negative * No other prior malignancy except basal cell or squamous cell skin cancer or a remote history of cancer now considered cured * No major organ dysfunction that would preclude transplantation * No major anticipated illness or organ failure that would preclude transplantation * No severe psychiatric illness or mental deficiency that would preclude giving informed consent or complying with study * No uncontrolled infection PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * See Disease Characteristics Endocrine therapy * Not specified Radiotherapy * See Disease Characteristics Surgery * Not specified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of graft failure 100 days post-transplant | — |
| Incidence of acute and chronic graft-vs-host disease100 days post-transplant | — |
| Transplant-related mortality 100 days post-transplant | — |
| Disease-free survival 100 days post-transplant | — |
| Overall survival 100 days post-transplant | — |
Countries
United States
Outcome results
None listed